Tuesday, 30 June 2020

Liquid Biopsy Market Dynamics, Forecast, Analysis And Supply Demand 2019

Market Insights:
Liquid biopsy overcomes these problems of tissue biopsy by using biomarkers present in samples such as blood, urine etc. and thus is a comparatively non-invasive technique. Liquid biopsy also provides greater information about the sample which is real time. The real time data can be used for monitoring and thereby determining the treatment for diseases such as cancer. The greater sensitivity of tissue biopsy coupled with the development of sophisticated detectors with extremely low detection rates have enabled the early detection of diseases which is the holy grail of cancer.
Biopsy involves extracting a sample of tissue and testing it for the presence of diseases especially cancer. Traditional tissue biopsy is a painful technique and also has a high rate of false results. Moreover the technique is costly, time consuming and not applicable for extracting samples such as those close to vital organs such as heart.
Segmentation:
Global Liquid Biopsy market has been segmented on the basis of biomarker type which comprises of circulating tumor cells (Ctcs), circulating tumor DNA (Ctdna), extracellular vesicles (Evs) and other biomarker. On the basis of application; market is segmented into cancer therapeutic application, reproductive health, and other therapeutic application. On the basis of sample; market is segmented into blood, urine and others. On the basis of end-users; market is segmented into hospitals and laboratories, academic and research centres and others.
Major Players
  • Guardant Health, Inc.,
  • Trovagene, Inc.,
  • RainDance Technologies, Inc.,
  • Agena Bioscience Inc. Inc.,
  • Admera Health,
  • Biocept, Inc.,
  • Circulogene Theranostics,
  • Inivata Ltd.,
  • SAGA Diagnostics AB,
  • Exosome Diagnostics and others.
Drivers
The market drivers for the liquid biopsy market are rising rates of cancer, growing investment in research and development, collaborations between companies and public organizations, rise in geriatric population, rising expenditure on health etc. The factors which are inhibiting the growth of the market includes the prohibitive costs associated with liquid biopsy and the differential awareness and availability between developing and the developed world. However, not all cancer patients benefit from early detection as some cancer types such as brain cancer and prostate cancer may lie dormant for many years. Further liquid biopsy is not all non-invasive as can be seen in case of using spinal fluid as sample.
Also the technique is not applicable to all types of cancer as some cancers such as brain cancer and prostate cancer may lie dormant for many years, and thus are either undetectable or detected very late which robs liquid biopsy of its advantages. Further liquid biopsy is not all non-invasive as can be seen in case of using spinal fluid as sample.
Regional Analysis:
Depending on geographic region, Liquid biopsy market is segmented into four key regions: Americas, Europe, Asia Pacific, and Middle East & Africa. Globally developed countries led by North America is the largest market for Liquid biopsy. Europe is the second-largest market for liquid biopsy. The developing regions market such as Asia pacific region and Middle East & Africa however is rising much faster.
Key findings
  • Circulating tumor cells (CTCs) segment dominates both in terms of market share as well as revenues, contributing approx. 55.48% of the revenue share of the liquid biopsy market.
  • On the basis of the therapeutic application, the segment for Cancer will reflect the highest growth potential, with over 82.83% of the market share by revenues. However, the urine sample segment is anticipated to witness noticeable growth.
  • The market for liquid biopsy is dominated by North America and Europe and this trend will continue. Asia-Pacific market is the fastest growing market and is expected to grow at a CAGR of 29.7% during forecasted period

Cranial Fixation and Stabilization Market 2019 - Opportunity, Driving Trends And Deep Study 2023

This cranial fixation and stabilization devices market size can be attributed to the growing healthcare market and the ever-expanding technology market. Advances in these fields have created an environment that is conducive to the development of specialized surgical procedures for traditionally high-risk surgeries.
According to the UN, globally, one in six individuals suffers from a neurological disorder. There are several invasive surgeries that being developed to treat such conditions, requiring cranial fixation and stabilization equipment.
The Global Cranial Fixation and Stabilization Market value is expected to reach USD 2.29 Billion by 2025, registering a CAGR of 8.90%.
SEGMENTATION
By Category
Cranial stabilization equipment is used to secure the head during surgery, while cranial fixation implements are tools required to maintain the structural stability of the head and neck.
  • Cranial Fixation Systems: Cranial fixation covers a wide array of tools and implements such as meshes, flap tube clamps, plates, and screws to be used during surgery. They are used predominantly for affixing bones, securing skin, and enhancing cranial integrity post-surgeries such as craniotomies.
  • Cranial Stabilization Systems: Cranial surgeries are usually very delicate and complex, necessitating the use of equipment to immobilize the head. This is accomplished by the use of cranial stabilization equipment such as skull clamps and horseshoe headrests.
By Product
  • Meshes: The leading market segment as 48% of all cranial injuries are maxillofacial. Over 52% of road accident-related injuries are mandibular fractures that require meshes.
  • Skull Clamps: Ideal for prolonged surgeries that require patient immobilization for long periods with limited soft tissue damage. Used to hold the head firmly in place during surgery.
  • Flap Tube Clamps: Used to attach cranial bones to the cranium during delicate surgeries when only a singular motion can be performed upon the afflicted area.
  • Horseshoe Headrests: Used in cases where head movement is not to be completely restrained and soft tissue damage needs to be minimized.
  • Plates: Used to seal gaping cranial wounds.
  • Screws: Facilitate the attachment of cranial bones.
  • Accessories: Include patient positioning systems and support systems.
By Type
  • Resorbable: Materials that are eventually broken down by the body. The growth of the segment is limited by the high costs of the equipment.
  • Non-Resorbable: These are biocompatible and offer unparalleled rigidity and stability to the cranium. Used extensively in developing countries due to their low costs.
By End User
  • Hospitals: The segment commands the largest share of the global cranial fixation and stabilization market as most cranial surgeries are performed in hospitals. Cranial surgeries require the latest equipment and amenities, along with a high level of expertise, which are offered by hospitals.
  • Ambulatory Surgical Centers: As emergency and temporary patient-stabilization surgeries are performed at these centers, the segment accounts for a small market share, which is somewhat offset by the higher revenue per surgery generated.
  • Others: This segment includes on-site trauma and emergency surgeries. This is a niche segment with growth potential due to the establishment of trauma centers at industrial complexes.
 By Region
  • Americas: Largest regional market, with North America accounting for 55% of the global market share.
  • Asia-Pacific: Fastest growing regional market
  • Europe: Second-largest market
  • Middle East & Africa
Key Players
  • Johnson & Johnson (US)
  • Stryker (US)
  • Ostomed (UK)
  • KLS Martin Group (Germany)
  • Medtronic (US)
  • Integra LifeSciences Corporation (US)
  • Braun Melsungen AG (Germany)
  • Changzhou Huida (China)
  • DePuy Synthes (US)
  • Evonos (Germany)
  • Jeil Medical (South Korea)
  • Medicon (Germany)
  • Micromar (Brazil)
  • NEOS Surgery (Spain)
  • Pro Med Instruments (Germany)
  • Zimmer Biomet (US)

Telehealth Market Revenue, Opportunity, Forecast And Value Chain Analysis 2019

Telehealth Market Overview
As per Market Research Future (MRFR) analysis, the Global Telehealth Market is expected to reach USD 16,173.8 million with a CAGR of 22.74% from 2017 to 2024 (forecast period).
Telehealth is the use of digital information and communication technologies to access healthcare facilities remotely for health management purposes. Telehealth connects patients to primary healthcare facilities through remote monitoring, video conferencing, electronic consultations, and wireless communication. Factors such as, the increase in the geriatric population, growing prevalence of chronic diseases and the lack of doctors are the key drivers of the telehealth industry's growth. Privacy and security issues and strict policy rules for telehealth services could impede market growth during the forecast period. 
Get a FREE Sample with Complete TOC By Considering the COVID-19 impact on Global Market @ https://www.marketresearchfuture.com/sample_request/900
Telehealth Market Dynamics
Telehealth could be used effectively to diagnose, treat, and support chronic diseases such as diabetes and cancer. Chronic diseases reduce the quality of life of an individual, particularly if left undiagnosed or untreated. As per the data by the Government of Canada, about 2.3 million people aged 12 and older were diagnosed with diabetes in 2017. In addition, according to the Chiron Health press release published in June 2016, an estimated 117 million people in the Americas have been affected by chronic diseases such as heart disease, stroke, depression, cancer, type 2 diabetes, obesity, and arthritis. Telehealth can be used to meet the growing demand for health services for cancer, diabetes, and other diseases in developing regions. As a result, the high prevalence of these diseases is expected to boost the growth during the forecast period.
There are some federal limitations, regulatory and legislative barriers to data privacy, cybersecurity, and care accuracy that have made adoption of telehealth and remote patient monitoring difficult. Secondly, the medical treatment given under the area of virtual treatment and telehealth was without incentives, with many limitations as to which type of care qualifies for medical reimbursement. Moreover, Healthcare provider required HIPAA to comply with the software and technology needed to offer telehealth services, and the breach of these laws resulted in substantial penalties. All of these factors are expected to impede the growth of the market during the forecast period. 
Covid-19 Analysis /Covid-19 Impact on the Global Telehealth Market
It didn't take a novel coronavirus for the telehealth industry to begin to gain momentum between healthcare providers and patients. Telehealth was already experiencing considerable momentum and development before this public health emergency, especially over the past few years, as technology has become more streamlined, and the young generation of tech-savvy is becoming more involved in this care model. The demand for telehealth is increasing, but many customers remain confused or unsure about its availability.
Statistically, 40% of doctors are providing treatment for coronavirus patients, and 60% of doctors are forced to abandon their treatment unless they have been told otherwise. Social distancing and lockdowns throughout countries due to COVID-19 forced non-urgent health care providers to shut their doors and encouraged many patients to receive treatment remotely. Owing to the volatility of the COVID-19 crisis, a number of health care providers are considering modifying their business model and introducing telehealth solutions as part of their daily medical system. Telehealth is no longer a secondary treatment option but a must-have option for health practitioners and patients.
Given the wide-reaching COVID-19 (Coronavirus) Impact on Telehealth Market, companies are on the lookout for new opportunities to sustain in the coming years. Gain new insights into the market and alternative solutions for keeping production steady in unforeseen circumstances.
Use of Telehealth Services in Fighting COVID-19
  • To minimize the risk of spread of COVID-19
  • Reduce the use of personal protective equipment (PPE) in outpatient services, which needs to be spared in more critical situations. Secure clinicians by reducing direct contact with contaminated patients. 
  • Suspected cases and milder cases of COVID-19 that do not require hospitalization can be monitored remotely, freeing up beds for severe cases.
Post COVID-19 Telehealth Scenario
  • The rapid expansion of telehealth services due to COVID-19 will have long-term implications, and solutions and services will remain readily accessible even after the end of the coronavirus pandemic.
  • As people have already seen telehealth in practice during this unpredictable period and are experiencing its benefits, in the future, the telehealth industry should see a rise in usage with improved functionality and accessibility worldwide.
  • As predicted, the relaxation of the HIPAA regulations and the breach penalty will be lifted after the pandemic. Care professionals and patients are likely to turn to HIPAA-compliant and more safe telehealth systems to receive medical attention.
Processes to be Streamlined Post the Pandemic
  • Government regulations need to be evaluated to protect the privacy of patient data and to ensure IT network security while offering the best medical care through virtual platforms.
  • Clinical protocols and workflows should be reviewed to ensure that remote care is used only for appropriate conditions and that the doctor-patient relationship is not jeopardized.
  • We, the people, need to ensure that our healthcare insurance programs have sufficient incentives for telehealth use.
  • Proper preparation needs to be given to healthcare workers as they change the way they function. 
Telehealth Market Segmentation
The global telehealth market report has been segmented into component, mode of delivery, application, and end-user.
By component, the global telehealth market has been segregated into services, software, and hardware. The services segment held the largest share due to the rising initiatives of key organizations. In contrast, the software segment is estimated to rise fastest due to a growing inclination towards telehealth software. The hardware industry was further sub-segmented into monitoring devices, medical peripherals, and others. The market for monitoring devices has been sub-categorized into stationary and wearable monitoring devices. The demand for medical peripherals was further classified into blood pressure monitors, ECG monitors, pulse oximeters, peak flow meters, blood glucose meters, otoscopes, and others. The software industry has been broken down into integrated software and stand-alone software. The market for services has also been listed as remote monitoring, real-time interactions, and store-and-forward consultations.
By mode of delivery, the global market for telehealth has been divided into web/cloud-based and on-premise. The web/cloud-based segment holds a significant share due to its broad preferability. In contrast, the on-premise segment is expected to be the fastest-growing segment due to rising awareness among hospital management.
By application, the global telehealth market has been categorized as radiology, cardiology, primary care, neurophysiology, and others. The radiology segment held a significant share due to the increased use of telehealth technologies in the radiology field. In contrast, the cardiology segment is expected to be the fastest-growing due to the rise in cardiovascular disease.
By the end-user, the global telehealth market has been classified as hospitals and clinics, diagnostic clinics, home care, and others. The hospitals and clinical segment held a significant share due to the increase in the number of hospitals using telehealth software. At the same time, the diagnostic clinical segment is expected to be the fastest growing segment due to an increasing tendency towards telehealth services. 
Telehealth Market Regional Analysis
Regionally, the global telehealth market share has been segmented into the Americas, Europe, the Asia Pacific, and the Middle East & Africa.
The Americas are expected to dominate the global demand for telehealth. It can be due to the growing acceptance of telehealth services in the United States. For example, in 2016, Kaiser Permanente, a California-based Integrated Managed Care Company, performed more consultations virtually than in person, i.e., almost 52% of the 110 million physician visits were through online portals, virtual visits, or apps.
The European market for telehealth is projected to be the second-largest market. The paradigm shift towards more structured and continuous monitoring of healthcare is expected to be a major factor in the industry's growth. In 2018, Italy had a market share of 12.4% for telehealth in Western Europe.
The Asia Pacific is emerged as the fastest-growing region on the global market due to a rise in the prevalence of chronic diseases, an increase in the geriatric population and a lack of technical personnel.
The Middle East & Africa are expected to see significant growth due to limited access and affordability of healthcare. 
Telehealth Market Key players
The prominent participants in the global telehealth market are 
  • AMD Global Telemedicine Inc. (US)
  • Siemens (Germany)
  • Allscripts Healthcare Solutions (US)
  • Boston Scientific Corporation (US)
  • Right Health (Canada)
  • American Well (US)
  • InTouch Technologies Inc. (US)
  • GlobalMed (US)
  • Care Innovations LLC (US)
  • Honeywell International Inc. (US)
  • Medtronic PLC (Ireland)
  • Dialogue (Canada)
  • Philips Healthcare (Netherlands)
  • Cerner Corporation (US)
  • Cisco Systems Inc. (US)
  • Maple (Canada)
  • Livecare Health (Canada)
Telehealth Industry News
American Well launched the American Well 760 Cart in January 2019, which enables remote specialists to be brought into the room by acute care teams at health systems. The new cart was designed for health systems running telehealth using American Well software or an existing Cisco infrastructure. 
Steps taken by governments around the globe to introduce telehealth services during COVID-19;
In the United States, the Federal Communications Commission (FCC) has set up a USD 200 million COVID-19 Telehealth Initiative to help qualified healthcare facilities continue to treat patients with telehealth technology. This initiative will help to make technology more available to patients who may otherwise be unable to access telehealth services.
Lowered Regulatory Barriers (Temporarily) - The regulatory changes have reduced or removed, at least temporarily, the obstacles that previously existed to enable providers and patients to opt for telehealth over in-person visits, when necessary.
On 17 March 2020, the U.S. Department of Health and Human Services Office for Civil Rights announced a series of restrictions against HIPAA violations during the pandemic to promote the use of standard video conferencing apps, including WhatsApp, Facetime, Zoom, and several others that do not have the necessary security features, are allowed (temporarily) to be used for teleconsultation.
The Japanese Ministry, METI, has launched a free remote health consultation service to address the related concerns of COVID-19. The main participants in this program are Mediplat and LINE Healthcare. During the duration from 11 to 31 March, the two companies managed to handle up to 5,000 consultations a day.
In April 2020, the Ministry of Health and NITI Aayog released guidelines for “Telemedicine” amidst COVID-19 in India. With these updated guidelines, 70% of the patient inquiries for consultations have increased.
Obtain Premium Research Report Details, Considering the impact of COVID-19 @ https://www.marketresearchfuture.com/reports/telehealth-market-900

Plasma Fractionation Market To Show Steady Growth, 2019

Plasma Fractionation Market Overview: 
The global plasma fractionation market is showing ample scope for growth and it is projected to secure a 6.5% CAGR during the forecast period of 2018 to 2023. Market Research Future (MRFR), in its attempt to understand the market proceedings, has revealed several factors that can impact the growth. The better technological influx and their easy integration in the mainstream, improvement in the infrastructure, and a rise in investment to boost the research works would help the global market achieve growth.  
However, the process is getting hindered in lesser-developed regions owing to which the market may find the growth a bit sluggish.  
Get a FREE Sample (Including COVID19 Impact Analysis, Full TOC, Tables and Figures) of Plasma Fractionation Market @ https://www.marketresearchfuture.com/sample_request/7397
Plasma Fractionation Market Segmentation: 
The global market for plasma fractionation has been segmented by market researchers on the basis of product, application, and end user. MRFR analysts help in a proper assessment of the market to assist players in increasing their profit margin.  
By product, the global market study on the plasma fractionation has been segmented into coagulation factor concentrates, protease inhibitors, albumin, immunoglobulin, and others. The immunoglobulin segment has been segmented further into subcutaneous immunoglobulin (SCIG), intravenous immunoglobulin (IVIG), and others. The coagulation factor concentrates segment encompasses Factor IX, Von Willebrand Factor, Factor VIII, Fibrinogen Concentrates, Prothrombin Complex Concentrate, and Factor XIII. 
By application, the global discussion on the plasma fractionation market includes neurology, hematology, immunology, hemato-oncology, pulmonology, rheumatology, critical care, and others. The immunology segment is getting significant traction to boost the treatment process against viral attacks.  
By end user, the global report on the plasma fractionation market includes clinical research laboratories, hospitals & clinics, academic institutes, and others. Various clinical research laboratories are impacting the global market as they are trying to develop new methods of treatments. The Academic institutes are also fetching revenues as they are getting bolstered by government and private funding.  
Plasma Fractionation Market Regional Analysis: 
The Americas would dominate the global Plasma Fractionation Market and it would be backed by the US. The infrastructural superiority, better inclusion of technology, and high rate of investment to support the process would ensure the market’s upward trajectory. Asia Pacific would register the fastest CAGR during the forecast period.  
Plasma Fractionation Market Competitive Landscape: 
The global market on the plasma fractionation is getting inspired by the contributions of companies by Biotest AG, China Biologic Products Holdings, Inc., Bio Products Laboratory (BPL), Grifols, S.A., Japan Blood Products Organization, CSL Limited, Green Cross Corporation, LFB group, Octapharma AG, Kedrion S.p.A, Shanghai RAAS, Shire, Sanquin, and others. These companies are trying to expand their portfolio through innovation, merger, acquisition, and joint venture. The process is witnessing a surge in funding for the research and development sector. This has led to the development of better marketing strategies, branding, and launching. MRFR recorded these moves to influence the study of the market and facilitate future strategy-making policies.  
Plasma Fractionation Industry News: 
In May 2020, Headspring, a company known for its leading presence in the strategy and development, announced a partnership with the Plasma Protein Therapeutics Association (PPTA). The attempt is to develop a state-of-the-art system and help in protecting and ensuring donor health and plasma safety. This will accelerate the production of life-saving plasma protein therapies (PPTs), which would be helpful in treating patients with rare, chronic diseases. PPTA is known for being collectors of source plasma used for fractionation. 
The global market for plasma fractionation is getting ample traction from the COVID-19 treatment demands. Plasma therapy is gaining ground to treat patients with the disease, which is boosting the market prospect of the plasma fractionation.  
Obtain Premium Research Report Details, Considering the impact of COVID-19 @ https://www.marketresearchfuture.com/reports/plasma-fractionation-market-7397

Atherectomy Devices Market Expected To Grow At High Cagr During Forecast Period 2019 – 2023

Market Scenario
Atherectomy devices are built to either shave, cut, vaporize, laser or sand the plaques. The devices come with different indications. Different atherectomy devices have been invented for commercial use. The location of the plaque and type of blockage influence the choice of atherectomy device to be used. Some atherectomy devices are used only in the larger arteries on the upper portion of the knee, while other devices come with smaller catheters that are suitable for operating the arteries below the knee.
Atherectomy is a technique applied to eliminate atherosclerotic plaque from affected arteries. The plaques are in either peripheral or coronary arterial vasculature and may have distinct characteristics depending on the nature of the plaque. Atherectomy is used widely in cure of both peripheral and coronary arterial ailments. It is a minimally invasive endovascular surgery.
The worldwide Atherectomy devices industry is likely to develop remarkably over the forecast period. It is projected that the global atherectomy devices market will register a CAGR of 6.12% over the forecast period of 2018–2023. In 2017, the estimated market value was around 1.09 billion.
The growing rate of peripheral and coronary arterial diseases coupled with increasing demand for minimally invasive techniques is predicted to boost the growth of the atherectomy devices market. Minimally invasive surgical techniques deliver quicker recovery, quick procedural time, lesser risk of infections and complications. The worldwide atherectomy devices market is likely to witness noteable surge in demand due to exponential growth in the incidence of lifestyle-related ailments and elderly population.
Segmentation
The global atherectomy devices market is segmented on the basis of product type, application, and end user.
Based on application, the atherectomy devices market is segmented into cardiovascular, neurovascular, peripheral vascular, and others.
The atherectomy devices market, by product type is categorised into directional atherectomy systems, orbital atherectomy systems, photo-ablative (laser) atherectomy systems, rotational atherectomy systems, and others.
The directional atherectomy systems segment is expected to hold the largest share owing to the high treatment rate, whereas the photo-ablative (laser) atherectomy systems is expected to be the fastest growing segment owing to the growing preference by surgeons.
On the basis of end user, the market is segmented into hospitals, ambulatory surgery centers, and others.
On the basis of region, the global atherectomy devices market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is sub-segmented into North America and Latin America. The North American region is further segmented into the US and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the UK, Spain, and the rest of Western Europe. The Asia-Pacific region is sub-segmented into Japan, China, India, Australia, South Korea, and the rest of Asia-Pacific. The atherectomy devices market in the Middle East and Africa has been segmented into the Middle East and Africa.
Regional Market Summary
Asia-Pacific was projected to be the fastest growing region for the global atherectomy devices market. This owes to the technological advancements resulting in the development of cost-effective atherectomy devices leading to high acceptance rate for the devices in the Asia-Pacific region. The Middle East and Africa holds the least share in the global atherectomy devices market due to the presence of economically diverse countries, and less initiatives taken by the government.
It is projected that the Americas dominated the global atherectomy devices market owing to the growth of the market in the North American region. This is largely attributed to the factors such as increase in research funding, and growing awareness about the high-end atherectomy devices among medical professionals. Europe is expected to hold the second largest share in the atherectomy devices market owing to growing healthcare infrastructure. Additionally, various initiatives by public and private organizations is anticipated to boost the growth of the atherectomy devices market.

Dental Bone Graft Substitutes Market Global Market By Treatments, Causes, Drugs And Diet 2019-2023

Market Scenario:
The increasing incidence of oral diseases such as, dental caries and periodontal diseases, growing ageing population, and growing medical tourism in developing countries are expected to drive the growth of market. Dental tourism is increasing because dental patients mostly from a developed country are getting attracted towards other developing countries. Dental patients prefer to travel to the countries because these countries are providing cost effective and high-quality treatment. Mostly, the treatments in the dental tourism centers around the demand for dental implants. Countries like Hungary, India, South Korea and Turkey are increasingly gaining popularity in the area of dental tourism for their low cost and effective oral health treatment. On other hand, lack of proper reimbursement and stringent regulations can restrain the market growth over the assessment period. Moreover, increasing burden of oral diseases drive the growth of the market. According to Centers for Disease Control and Prevention (CDC), about 64.7 million Americans were suffered with periodontal disease.
Global dental bone graft substitutes market trends expected to lead industry growth significantly over the forecast period. It is anticipated that the market held value of USD 461.3 million in 2017 and is projected to grow at a CAGR of 9.4% over the forecast period.
Global Dental Bone Graft Substitutes, by Key Players
  • Biohorizons Iph, Inc. (US)
  • Geistlich Pharma AG (Switzerland)
  • Dentsply Sirona (US)
  • Institut Straumann AG (Switzerland)
  • Medtronic Plc (US)
  • Zimmer Biomet Dental (US)
  • Dentium (South Korea)
  • LifeNet Health (US)
  • Orthogen, LLC (US)
Segmentation
The global dental bone graft substitutes market has been segmented into type, application, and end user.
Based on type, dental bone graft substitutes market is segmented into allograft, xenograft, alloplast, and others.
Based on application, dental bone graft substitutes market is segmented into ridge augmentation, sinus lift, socket preservation, periodontal defect, and implant bone regeneration.
Based on end user, dental bone graft substitutes market is segmented into dental clinics, hospitals, and others. The dental clinics segment is expected to account for the largest share segment of the market in 2017.
The dental bone graft substitutes market segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The dental bone graft substitutes market in the Americas further segmented into North America and South America, with the North American market divided into the US and Canada.
The European dental bone graft substitutes market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The dental bone graft substitutes market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The dental bone graft substitutes market in the Middle East & Africa segmented into the Middle East and Africa.
Regional Summary
Geographically, the Europe is expected to dominate the global dental bone graft substitutes market owing to the presence of well-established players, increasing incidence of oral diseases namely, dental caries and periodontal diseases, and growing ageing population. The Americas including US Dental Bone Graft Substitutes Market is expected to hold the second largest position in the global dental bone graft substitutes market. Asia-Pacific is expected to be the fastest growing market owing to growing medical tourism in developing countries and growing ageing population. Furthermore, the Middle East and Africa region is expected to account for the least market share in the global dental bone graft substitutes market.

Antihypertensive Drugs Market 2019 Analysis, Opportunities And Forecast To 2023

According to a recent study report published by the Market Research Future, The global market of  Anti-Hypertensive Drugs was valued at $32.2 billion in 2015, and is projected to reach $ USD 41.2 billion by 2023. Thus the anti-hypertensive drugs market growth is anticipated to observe a sluggish CAGR of 2.73% during 2016 to 2022.
Anti-Hypertensive Drugs are used to treat hypertension (high blood pressure). Hypertension is a state of chronic elevated arterial blood pressure at or greater than 140/90 mm Hg for adults. Hypertension is one of the most powerful risk factors for cardiovascular morbidity and mortality. There exact cause of hypertension is unknown but is said that unhealthy, heady lifestyle and ageing mirror such disorders as “Hypertension”.
The major market driving factors for secondary hypertension are greater detection and early diagnosis. Rise in the prevalence diseases such as kidney problems, thyroid problems, adrenal gland tumours, heart ailments, chronic alcohol use etc. in which anti-hypertensive drugs are used; are some of the other factors driving the growth of the Anti-Hypertensive Drugs market. The constraints however are overwhelming and include patent expiries such as Actelion's Tracleer (2015), and United Therapeutic's Remodulin (2014). Other blockbuster’s such as Novartis's Diovan and Exforge, Sanofi Aventis's Avapro (2012) etc are also off-patent.
Many antihypertensive drugs have their primary action on systemic vascular resistance. Some of these drugs produce vasodilation by interfering with sympathetic adrenergic vascular tone (sympatholytics) or by blocking the formation of angiotensin II or its vascular receptors. Other drugs are direct arterial dilators, and some are mixed arterial and venous dilators. Although less commonly used because of a high incidence of side effects, there are drugs that act on regions in the brain that control sympathetic autonomic outflow. By reducing sympathetic efferent activity, centrally acting drugs decrease arterial pressure by decreasing systemic vascular resistance and cardiac output.
Some antihypertensive drugs, most notably beta-blockers, depress heart rate and contractility (this decreases stroke volume) by blocking the influence of sympathetic nerves on the heart. Calcium-channel blockers, especially those that are more cardioselective, also reduce cardiac output by decreasing heart rate and contractility. Some calcium-channel blockers (most notably the dihydropyridines) are more selective for the systemic vasculature and therefore reduce systemic vascular resistance.
Segmentation
The Anti-Hypertensive Market can be segmented in to 4 key dynamics for the convenience of the report and enhanced understanding;
Segmentation By Pharmacological Class               : Comprises Diuretics, ACE Inhibitors, Calcium Channel Blockers, Adrenergic Blocker and other.
Segmentation By Hypertension Type                      : Comprises Systemic and Pulmonary Hypertension Drugs and other.
Segmentation By Disease Source                              : Comprises Primary and Secondary.
Segmentation By Regions                                            : Comprises Geographical regions - North America, Europe, APAC, including Anti-Hypertensive Drugs Market in India and Rest of the World.
Regional Analysis
The antihypertensive drugs market covers growth drivers in the following regions, namely Americas, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA). The Americas accounted for a large market share owing to high prevalence of hypertension linked to cardiovascular and renal disorders. Drives by government and non-government organizations for creating awareness of the medical condition are likely to bolster the revenue of the antihypertensive drugs market in Americas.
The Europe region was the second-largest due to rise of cardiovascular diseases, unhealthy diets, and increase noticed in obesity levels of patients. According to the European Heart Network in 2017, heart diseases accounted for 3.9 million deaths. Germany, France, and the U.K. are expected to be the prime contributors to the antihypertensive drugs market in Europe.
The APAC region is projected to exhibit a robust pace owing to increased healthcare budget and rise in disposable income levels of patients. The setup of research and development centers to fast-track the commoditization of drugs for treating hypertension is likely to boost the APAC antihypertensive drugs market.
Key Players
Novartis AG, Daiichi Sankyo Company Limited, Acetelion Ltd, Boehringer Ingelheim, Sanofi S.A., Astra Zeneca plc, Ranbaxy Laboratories Limited, Inc., Takeda Pharmaceuticals Company Limited, Pfizer Inc. are some of the prominent players at the forefront of competition in the Global Market of Anti-Hypertensive Drugs and are profiled in MRFR Analysis.